Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Receivables: 2017-2025

Historic Receivables for Cidara Therapeutics (CDTX) over the last 8 years, with Sep 2025 value amounting to $1.9 million.

  • Cidara Therapeutics' Receivables rose 9.54% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 72.02%. This contributed to the annual value of $1.7 million for FY2024, which is 87.96% down from last year.
  • According to the latest figures from Q3 2025, Cidara Therapeutics' Receivables is $1.9 million, which was up 0.11% from $1.9 million recorded in Q2 2025.
  • Cidara Therapeutics' Receivables' 5-year high stood at $46.1 million during Q1 2023, with a 5-year trough of $11,000 in Q1 2021.
  • Its 3-year average for Receivables is $7.9 million, with a median of $2.3 million in 2024.
  • In the last 5 years, Cidara Therapeutics' Receivables crashed by 99.83% in 2021 and then soared by 157,927.27% in 2022.
  • Over the past 5 years, Cidara Therapeutics' Receivables (Quarterly) stood at $8.2 million in 2021, then soared by 40.18% to $11.4 million in 2022, then increased by 23.11% to $14.1 million in 2023, then plummeted by 87.96% to $1.7 million in 2024, then grew by 9.54% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.9 million for Q2 2025, and $1.7 million during Q1 2025.